Oxidative stress markers are increased in patients with mastocytosis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 4, 2015, Pages 436-442

  Gangemi, S ^a,b   Minciullo, P L ^a   Magliacane, D ^c   Saitta, S ^a   Loffredo, S ^d   Saija, A ^e   Cristani, M ^e   Marone, G ^d   Triggiani, M ^f  

^a UNIVERSITY OF MESSINA   (Italy)

^b CNR   (Italy)

^c Santa Maria della Speranza   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

Author keywords

advanced glycation end product; advanced oxidation protein product; mast cell; mastocytosis; oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; TRYPTASE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; BONE MARROW BIOPSY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; HOT FLUSH; HUMAN; MALE; MAST CELL; MASTOCYTOSIS; MIDDLE AGED; OSTEOPOROSIS; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SYSTEMIC MASTOCYTOSIS; URTICARIA PIGMENTOSA; YOUNG ADULT; BLOOD; CASE CONTROL STUDY; INFANT; METABOLISM;

ADOLESCENT; ADULT; ADVANCED OXIDATION PROTEIN PRODUCTS; AGED; BIOMARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFANT; MALE; MAST CELLS; MASTOCYTOSIS; MIDDLE AGED; OXIDATIVE STRESS; TRYPTASES; YOUNG ADULT;

EID: 84925738954     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12571     Document Type: Article

References (34)

1. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37: 435-453.
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25: 603-625.
3. Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 2003; 27: 635-641.
4. Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy 2014; 69: 1267-1274.
5. Valent P, Horny HP, Triggiani M, Arock M,. Clinical and laboratory parameters of mast cells activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol 2011; 156: 119-127.
6. Castells M, Metcalfe DD, Escribano L,. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12: 259-270.
7. Carter MC, Metcalfe DD, Komarow HD,. Mastocytosis. Immunol Allergy Clin North Am 2014; 34: 181-196.
8. Gonzalez de Olano D, de la Hoz Caballer B, Nunez-Lopez R, Sanchez Munoz L, Cuevas Agustìn M, Dieguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37: 1547-1555.
9. Brockow K, Jofer C, Behrendt H, Ring J,. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-232.
10. Holguin F, Fitzpatrick A,. Obesity, asthma, and oxidative stress. J Appl Physiol 2010; 108: 754-759.
11. Bowler RP, Crapo JD,. Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol 2002; 110: 349-356.
12. Di Lorenzo G, Minciullo PL, Leto-Barone MS, La Piana S, La Porta G, Saija A, et al. Differences in the behavior of advanced glycation end products and advanced oxidation protein products in patients with allergic rhinitis. J Investig Allergol Clin Immunol 2013; 23: 101-106.
13. Hochman DJ, Collaco CR, Brooks EG,. Acrolein induction of oxidative stress and degranulation in mast cells. Environ Toxicol 2014; 29: 908-915.
14. Finotello R, Pasquini A, Meucci V, Lippi I, Rota A, Guidi G, et al. Redox status evaluation in dogs affected by mast cell tumour. Vet Comp Oncol 2014; 12: 120-129.
15. Kaida S, Ohta Y, Imai Y, Ohashi K, Kawanishi M,. Compound 48/80 causes oxidative stress in the adrenal gland of rats through mast cell degranulation. Free Radic Res 2010; 44: 171-180.
16. Spatari G, Saitta S, Cimino F, Sapienza D, Quattrocchi P, Carrieri M, et al. Increased serum levels of advanced oxidation protein products and glycation end products in subjects exposed to low-dose benzene. Int J Hyg Environ Health 2012; 215: 389-392.
17. Gangemi S, Allegra A, Aguennouz M, Alonci A, Speciale A, Cannavò A, et al. Relationship between advanced oxidation protein products, advanced glycation end products, and S-nitrosylated proteins with biological risk and MDR-1 polymorphisms in patients affected by B-chronic lymphocytic leukemia. Cancer Invest 2012; 30: 20-26.
18. Musolino C, Allegra A, Saija A, Alonci A, Russo S, Spatari G, et al. Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia. Clin Biochem 2012; 45: 1439-1443.
19. Kanazawa H, Tochino Y, Kyoh S, Ichimaru Y, Asai K, Hirata K,. Potential roles of pentosidine in age-related and disease-related impairment of pulmonary functions in patients with asthma. J Allergy Clin Immunol 2011; 127: 899-904.
20. Gangemi S, Allegra A, Alonci A, Cristani M, Russo S, Speciale A, et al. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. Inflamm Res 2012; 61: 1063-1067.
21. de Groot L, Hinkema H, Westra J, Smit AJ, Kallenberg CG, Bijl M, et al. Advanced glycation endproducts are increased in rheumatoid arthritis patients with controlled disease. Arthritis Res Ther 2011; 13: R205.
22. Sternberg Z, Ostrow P, Vaughan M, Chichelli T, Munschauer F,. AGE-RAGE in multiple sclerosis brain. Immunol Invest 2011; 40: 197-205.
23. Wu L, Ma L, Nicholson LF, Black PN,. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2010; 105: 329-336.
24. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JW,. The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999; 104: 103-113.
25. Brockow K, Akin C, Huber M, Metcalfe DD,. IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis. Clin Immunol 2005; 115: 216-223.
26. Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S, Forster A, et al. Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol 2013; 132: 232-235.
27. Kushnir-Sukhov NM, Brittain E, Scott L, Metcalfe DD,. Clinical correlates of blood serotonin levels in patients with mastocytosis. Eur J Clin Invest 2008; 38: 953-958.
28. Misciagna G, De Michele G, Trevisan M,. Non enzymatic glycated proteins in the blood and cardiovascular disease. Curr Pharm Des 2007; 13: 3688-3695.
29. Yoshimaru T, Suzuki Y, Inoue T, Nishida S, Ra C,. Extracellular superoxide released from mitochondria mediates mast cell death by advanced glycation end products. Biochim Biophys Acta 2008; 1783: 2332-2343.
30. Sick E, Brehin S, Andrè P, Coupin G, Landry Y, Takeda K, et al. Advanced glycation end products (AGEs) activate mast cells. Br J Pharmacol 2010; 161: 442-455.
31. Sorci G, Riuzzi F, Giambanco I, Donato R,. RAGE in tissue homeostasis, repair and regeneration. Biochim Biophys Acta 2013; 1833: 101-109.
32. Bordignon M, Da Dalt L, Marinelli L, Gabai G,. Advanced oxidation protein products are generated by bovine neutrophils and inhibit free radical production in vitro. Vet J 2014; 199: 162-168.
33. Ristow M, Schmeisser S,. Extending life span by increasing oxidative stress. Free Radic Biol Med 2011; 51: 327-336.
34. Can C, Tore F, Tuncel N, Uysal O, Gurer F, Ak D, et al. Protective effect of vasoactive intestinal peptide on testicular torsion-detorsion injury: association with heparin-containing mast cells. Urology 2004; 63: 195-200.